Literature DB >> 24045761

A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.

Alexios Matikas1, Nikolaos Vardakis, John Souglakos, Vassilios Georgoulias.   

Abstract

The link between cancer and venous thromboembolism is well known, with an annual incidence rate of venous thromboembolism between 0.5% and 20% depending on the primary site and background risk factors. Current guidelines suggest treatment with low-molecular-weight heparin over oral vitamin K antagonists. However, data regarding the management of recurrent venous thromboembolism when the patient is under treatment with anticoagulants are sparse. In this article we present a patient with multiple thromboembolic events in unusual sites despite anticoagulant treatment and we discuss the management options.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24045761      PMCID: PMC3794231          DOI: 10.1136/bcr-2013-200502

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Coagulation and cancer: biological and clinical aspects.

Authors:  A Falanga; M Marchetti; A Vignoli
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

Review 2.  Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue.

Authors:  S G Gordon; W P Mielicki
Journal:  Blood Coagul Fibrinolysis       Date:  1997-03       Impact factor: 1.276

3.  Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.

Authors:  Martha L Louzada; Marc Carrier; Alejandro Lazo-Langner; Vi Dao; Michael J Kovacs; Timothy O Ramsay; Marc A Rodger; Jerry Zhang; Agnes Y Y Lee; Guy Meyer; Philip S Wells
Journal:  Circulation       Date:  2012-06-07       Impact factor: 29.690

Review 4.  Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

Authors:  Sonia Seng; Ziyue Liu; Sophia K Chiu; Tracy Proverbs-Singh; Guru Sonpavde; Toni K Choueiri; Che-Kai Tsao; Menggang Yu; Noah M Hahn; William K Oh; Matthew D Galsky
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

5.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

6.  Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Kenneth A Bauer; Maria B Donati; Michael Gould; Meyer M Samama; Jeffrey I Weitz
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

7.  Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.

Authors:  Jeffrey I Zwicker; Howard A Liebman; Donna Neuberg; Romaric Lacroix; Kenneth A Bauer; Barbara C Furie; Bruce Furie
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

Review 8.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Gary H Lyman; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Ann Alexis Prestrud; Anna Falanga
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

9.  Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

Authors:  M Carrier; G Le Gal; R Cho; S Tierney; M Rodger; A Y Lee
Journal:  J Thromb Haemost       Date:  2009-02-24       Impact factor: 5.824

Review 10.  Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.

Authors:  Freesia Horsted; Joe West; Matthew J Grainge
Journal:  PLoS Med       Date:  2012-07-31       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.